Riskpilot← Back to searchSign inGet full accessSANOFI-AVENTIS NORGE AS
ASActiveOrg 976335147Professor Kohtsvei 5-17, 1325 LysakerWholesale of pharmaceutical and medical goods · NACE 4646Est. 199665 employeeswww.sanofi.com
Revenue 2024
NOK 844,2M
+10% vs 2023
EBITDA margin
6.0%
+29% vs 2023
Equity ratio
4.1%
Financial strength
Net profit 2024
NOK 37,5M
+18% vs 2023
| Revenue | NOK 844,2M | +10% |
| EBITDA | NOK 50,9M | +29% |
| Net profit | NOK 37,5M | +18% |
| Total assets | NOK 359M | +2% |
| Equity | NOK 14,9M | +182% |
| Employees | 65 | — |
Legal name
SANOFI-AVENTIS NORGE AS
Org number
976335147
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
26. mars 1996
Share capital
NOK 1 820 000
Employees
65 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap. Daglig leder alene. Styrets leder alene.
Address
Professor Kohtsvei 5-17, 1325 Lysaker
Phone
+4748053939
Website
www.sanofi.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 796 842 | 740 631 | 705 599 | 766 969 | 844 226 |
| Staff expenses | −110 847 | −107 102 | −101 097 | −96 045 | −99 925 |
| EBITDA | 131 656 | 39 272 | 59 265 | 39 579 | 50 889 |
| Depreciation & amort. | −2 856 | −9 274 | −324 | −398 | −460 |
| EBIT | 128 800 | 29 998 | 58 941 | 39 181 | 50 429 |
| Net financials | −896 | −913 | 611 | 2 818 | −1 699 |
| Profit before tax | 127 904 | 29 085 | 59 552 | 41 999 | 48 730 |
| Tax | 28 229 | 6 651 | 13 847 | 10 218 | 11 278 |
| Net profit | 99 675 | 22 434 | 45 705 | 31 781 | 37 452 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 298 147 | 326 202 | 398 813 | 351 862 | 359 000 |
| Equity | 131 840 | 154 274 | 50 946 | 5 273 | 14 881 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 166 306 | 171 928 | 347 867 | 346 589 | 344 119 |
| Total debt | 166 306 | 171 928 | 347 867 | 346 589 | 344 119 |
EBITDA margin
6.0%
This company
15.8%
Market median
-62% vs market
20202024
Equity ratio
4.1%
This company
38.2%
Market median
-89% vs market
20202024
Return on equity
251.7%
This company
18.4%
Market median
+1268% vs market
20202024
Net profit margin
4.4%
This company
8.1%
Market median
-46% vs market
20202024
Asset turnover
2.35×
This company
1.12×
Market median
+110% vs market
20202024
Debt / equity
23.12×
This company
0.62×
Market median
-3629% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
BM Chief Executive Officer | Chief Executive Officer | 2017 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2023 | |
| Board of Directors | 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100% | 100% | 2022 | |
Sanofiaventis Participations Fra | Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of SANOFI-AVENTIS NORGE AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Britt Moe Flatla | Chief Executive Officer | 0 companies |
| Per Harald Aabakken | Chairman | 0 companies |
| Stine Helsem Eide | Board of Directors | 0 companies |